Hold Rating for Neumora Therapeutics Amid Disappointing Phase …

Jan 3, 2025 · Tessa Romero has given her Hold rating due to a combination of factors affecting Neumora Therapeutics, Inc. One of the primary reasons is the disappointing results from the …

$21
OFF

Neumora Therapeutics Inc. - MarketWatch

2 weeks from now

6 days ago · Neumora Therapeutics initiated with overweight rating and $21 price target at J.P. Morgan Oct. 10, 2023 at 6:48 a.m. ET by Steve Gelsi Amgen discloses more than $400 million …

marketwatch.com

80%
OFF

Neumora Fails Phase 3 Depression Trial, Sending Stock Down 80%

2 weeks from now

Jan 2, 2025 · The first of three late-stage readouts on Neumora’s lead drug candidate has ended in failure, wiping more than 80% off the value of the biotech. Neumora fails phase 3 …

fiercebiotech.com

80%
OFF

Neumora Nosedives 80% At Pre-Market On Failed Depression …

2 weeks from now

Jan 2, 2025 · Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing results from the Phase 3 trial of navacaprant, …

yahoo.com

$2.28
OFF

Neumora Therapeutics' (NMRA) Outperform Rating Reiterated

2 weeks from now

1 day ago · Get Our Latest Stock Report on Neumora Therapeutics Neumora Therapeutics Stock Performance. Shares of Neumora Therapeutics stock opened at $2.28 on Wednesday. The …

marketbeat.com

80%
OFF

Neumora Shares Plunge As Navacaprant Misses Key Endpoints In …

2 weeks from now

Jan 2, 2025 · (RTTNews) - Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of topline results from its …

businessinsider.com

80%
OFF

Neumora Shares Plunge As Navacaprant Misses Key Endpoints In …

2 weeks from now

Jan 2, 2025 · Shares of Neumora Therapeutics, Inc. are down more than 80% at $1.81 in premarket trading Thursday, following the release of topline results from its Phase 3 …

rttnews.com

$30.00
OFF

Positive Outlook For Neumora Therapeutics Amid Key Milestones …

2 weeks from now

Dec 16, 2024 · Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report), retaining the price target of $30.00. Discover …

businessinsider.com

FAQs about Hold Rating for Neumora Therapeutics Amid Disappointing Phase … Coupon?

Should you buy neumora Therapeutics (NMRA – research report)?

J.P. Morgan analyst Tessa Romero downgraded the rating on Neumora Therapeutics, Inc. (NMRA – Research Report) to a Hold today, setting a price target of $15.00. Tessa Romero’s rating is based on the anticipated results from the phase 3 KOASTAL-1 trial for Neumora Therapeutics’ navacaprant, which are expected in the fourth quarter of 2024. ...

Should you buy neumora (neumora) stock?

This differentiation could provide a competitive edge in the market, supporting Tsao’s positive outlook and Buy rating for Neumora’s stock. Tsao covers the Healthcare sector, focusing on stocks such as Disc Medicine, SAGE Therapeutics, and Xenon. ...

Why did neumora Therapeutics drop 80% in its share price?

Credit: Ground Picture via Shutterstock ·Pharmaceutical Technology·Ground Picture via Shutterstock Neumora Therapeutics saw a drop of more than 80% in its share price following the announcement of a Phase III failure in major depressive disorder (MDD). ...

Why did neumora (NMRA) nosedive 80 percent during pre-market trading?

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing results from the Phase 3 trial of navacaprant, a drug being developed to treat major depressive disorders. A man leaning on a wooden table. Photo by Andrew Neel on Pexels ...

What was neumora Therapeutics' stock price on January 1st 2025?

Neumora Therapeutics' stock was trading at $10.60 on January 1st, 2025. Since then, NMRA stock has decreased by 79.5% and is now trading at $2.17. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) posted its quarterly earnings data on Tuesday, November, 12th. ...

When did neumora Therapeutics IPO?

Neumora Therapeutics (NMRA) raised $250 million in an IPO on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. ...